Precision highlights role of ChemoFx ...

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

There are 1 comment on the News-Medical.Net story from Jan 21, 2011, titled Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer. In it, News-Medical.Net reports that:

In a new study in which Precision Therapeutics' Multi- Gene Predictors were independently validated by investigators at US Oncology and MD Anderson, Precision highlights the potential role of the ChemoFxA in vitro chemosensitivity test and multi- gene predictors in determining a patient's likelihood of response to multi-drug chemotherapy regimens ...

Join the discussion below, or Read more at News-Medical.Net.

Since: Dec 05

Reading, PA

#1 Jan 22, 2011
The use of RT-PCR and DNA microarrays in personalized oncology is analogous to the introduction of the personal computer. Dazzling hardware in search of a killer application. So what research scientists in universities and cancer centers have been doing for the past ten years is to try and figure out a way to use this dazzling technology to look for patterns of gene expression which correlate with and predict for the activity of anticancer drugs.

Academics are besides themselves over the promise of genome sequencing. It seems so cool that it simply must be good for something. How about in the area of identifying drugs which will work in individual patients? All DNA or RNA-type tests are based on "population" research. They base their predictions on the fact that a higher percentage of people with similar genetic profiles or specific mutations may tend to respond better to certain drugs. This is not really "personalized" medicine, but a refinement of statistical data.

The particular sequence of DNA that an organism possess (genotype) does not determine what bodily or behaviorial form (phenotype) the organism will finally display. Among other things, environmental influences can cause the suppression of some gene functions and the activation of others. Our knowledge of genomic complexity tells us that genes and parts of genes interact with other genes, as do their protein products, and the whole system is constantly being affected by internal and external environmental factors.

The gene may not be central to the phenotype at all, or at least it shares the spotlight with other influences. Environmental tissue and cytoplasmic factors clearly dominate the phenotypic expression processes, which may in turn, be affected by a variety of unpredictable protein-interaction events. A challenge facing pharmacogenetics is the number and complexity of interactions a drug has with biological molecules in the body. Variations in many different molecules may influence how someone responds to a medicine. Teasing out the genetic patterns associated with particular drug responses could involve some intricate and time-consuming scientific detective work.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

US Oncology Discussions

Title Updated Last By Comments
News Cardinal loaded with optimism after spinoff (Nov '10) Nov '10 Don Lewis 4
News US Oncology Applauds Journal Of Clinical Oncolo... (May '08) May '08 gdpawel 1
News Heavy charges weigh on U.S. Oncology first-quar... (May '07) May '07 gdpawel 2